Michael Egholm, Standard BioTools president and CEO (IsoPlexis)

Eli Cas­din co-leads $250M in­fu­sion in­to mi­croflu­idics play­er that land­ed NIH fund­ing for Covid-19 test­ing

In about 17 months, Flu­idigm has gone from work­ing with sharks to Vikings.

The South San Fran­cis­co-based com­pa­ny, which land­ed NIH mon­ey in a Shark Tank-style pro­gram for Covid-19 test­ing, an­nounced that it will take on an in­vest­ment worth $250 mil­lion from Cas­din Cap­i­tal and Viking Glob­al In­vestors. It will al­so re­brand, and call it­self Stan­dard BioTools. The in­vest­ment will help the com­pa­ny fo­cus on the high­est growth ar­eas of dis­cov­ery and de­vel­op­ment and ex­pand its CRO and CMO ser­vice providers. Right now, the com­pa­ny’s cus­tomer reach is lim­it­ed to ba­sic re­search, it said.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.